



Cyclacel Pharmaceuticals, Inc.  
 Investor Relations Department  
 200 Connell Drive, Suite 1500  
 Berkeley Heights, NJ 07922  
 United States

[Visit IR website](#)

[Sign-up for email alerts](#)

**NASDAQ: CYCC <sup>1</sup>**

Last Trade:	1.86
Trade Time:	11:19 AM ET Sep 22, 2017
Change:	-0.38 (17.008%)
Day Range	1.85 - 2.27
52-Week Range	1.56 - 10.90
Volume	3,140,837
Market Cap. (\$M)	21.193
Shares Out (M)	11.400

<sup>1</sup> The stock information is provided by eSignal, stock charts are provided by EDGAR Online. Stock information is delayed approximately 20 minutes.

## Company Profile

We are a development-stage biopharmaceutical company dedicated to the development and commercialization of novel, mechanism-targeted drugs to treat human cancers and other serious disorders. Our strategy is to build a diversified biopharmaceutical business focused in hematology and oncology based on a portfolio of commercial products and a development pipeline of novel drug candidates.... [\(more\)](#)

## Stock Performance



## Press Releases [\[ View all \]](#)

- Sep 21, 2017  
[Cyclacel Pharmaceuticals to Present at the Ladenburg Thalmann 2017 Healthcare Conference](#)
- Sep 8, 2017  
[Cyclacel Pharmaceuticals to Present at the 19th Annual Rodman & Renshaw Global Investment Conference](#)
- Aug 9, 2017  
[Cyclacel Pharmaceuticals Reports Second Quarter 2017 Financial Results](#)
- Aug 7, 2017  
[Cyclacel Announces Selection of Recommended Phase 2 Dose for CYC065 and Evidence of Durable Target Engagement and Mcl-1 Biomarker Suppression](#)
- Aug 2, 2017  
[Cyclacel Pharmaceuticals to Release Second Quarter 2017 Financial Results](#)

## Events [\[ View all \]](#)

There are no events to display at this time. Please check back later.

## Financials [\[ View all \]](#)

- Mar 31, 2017  
[Annual Report \(10-K\)](#)
- Apr 12, 2017  
[Definitive Proxy Statement](#)
- Aug 10, 2017  
[Quarterly Report \(10-Q\)](#)
- May 12, 2017  
[Quarterly Report \(10-Q\)](#)
- Nov 14, 2016  
[Quarterly Report \(10-Q\)](#)